Tenax Therapeutics, Inc.
NASDAQ:TENXBiotechnology
+$0.10 today
- Market cap
- $50.66M
- Beta
- 0.97
- P/E (TTM)
- -9.4
- EPS (TTM)
- -$1.28
Volume 0.70M
Average 0.62M
TENX Total Current Liabilities
All obligations due within one year.
Tenax Therapeutics, Inc.NASDAQ: TENX
Total Current Liabilities · Q1 FY2026 · quarter ended Mar 2026
Total current liabilities rises 206.6% from a year ago
Total current liabilities stood at $8.49M at the end of Q1 FY2026, up 206.6% from a year earlier and up 18.6% from the prior quarter. Over 3 fiscal years it compounded at +57.0% a year.
Context
- Total current liabilities amounted to 6.9% of total assets at the end of Q1 FY2026, up 4.4 pp from a year earlier.
- Total current liabilities increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether total current liabilities keeps rising in the next quarterly balance sheet after a +206.6% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Current Liabilities history
USD · from the balance sheet
- Latest · FY2025
- 7.16M USD
- Year-over-year change
- +52.5%
- 4-year CAGR
- +46.3%
| Period | Period end | Total Current Liabilities | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 7.16M | +52.5% |
| FY2024 | 2024-12-31 | 4.69M | +30.9% |
| FY2023 | 2023-12-31 | 3.59M | +94.1% |
| FY2022 | 2022-12-31 | 1.85M | +18.1% |
| FY2021 | 2021-12-31 | 1.56M | — |
Total Current Liabilities vs competitors
How TENX compares with its peers on the latest reported figures
- TENX's Mar 2026 total current liabilities of $8.49M is the 6th highest of the 7 companies compared; the peer median is $11.19M.
- Its year-over-year change of +206.6% is the 2nd highest of 7, against a peer median of -8.6%.
- Total current liabilities amounts to 6.9% of total assets for TENX, versus a peer median of 6.6%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Jun 2026 | $3.96B | +156415.7% | +18.5% | 4.2% | |
| Mar 2026 | $16.22M | -44.8% | +68.1% | 41.8% | |
| Jun 2026 | $11.71M | +9.6% | -10.7% | 4.9% | |
| Mar 2026 | $10.67M | -26.8% | -41.9% | 16.8% | |
| Mar 2026 | $9.58M | +51.2% | +17.5% | 6.8% | |
| Mar 2026 | $8.49M | +206.6% | +57.0% | 6.9% | |
| Mar 2026 | $5.56M | -30.6% | +6.7% | 6.4% | |
| Peer median (excluding TENX) | $11.19M | -8.6% | +12.1% | 6.6% | |
Competitors are the stored peer set for TENX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Tenax Therapeutics, Inc.
NASDAQ:TENX
Intrinsic Alpha fair value
Locked
Current Price
$1.91
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.